Blockchain Registration Transaction Record

Clene Secures $10M Debt Facility for ALS Drug Approval Process

Clene (NASDAQ: CLNN) secures a $10 million debt facility to support the new drug application for lead candidate CNM-Au8 for ALS. CEO Rob Etherington believes this funding will give the company the necessary resources to generate additional data for FDA approval.

Clene Secures $10M Debt Facility for ALS Drug Approval Process

This news highlights Clene's progress in securing funding for its drug development efforts, specifically focusing on treating neurodegenerative diseases like ALS. The support of the FDA and the company's strategic financial decisions signify a step forward in potentially providing effective treatment options for patients with debilitating conditions.

BlockchainDetails
Contract Address0x0553B273B8eBf464Bd2a37C259F0eEBb3d70Fd71
Transaction ID0xb7a201bb63a435087c35acbdbcf366d37a825d1493adb55abf065c7847922669
Account0xdBdE7c76e403a5923F3dD4F050Dbbf5c2077BB20
Chainpolygon-main
NewsRamp Digital FingerprintchipXVZv-b0811f2593789b7c1706a52c87b955c5